- Home
- EXOZ vs ACHV Comparison
EXOZ vs ACHV Comparison
Compare EXOZ & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXOZ
- ACHV
- Stock Information
- Founded
- EXOZ 2014
- ACHV N/A
- Country
- EXOZ United States
- ACHV Canada
- Employees
- EXOZ N/A
- ACHV N/A
- Industry
- EXOZ
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EXOZ
- ACHV Health Care
- Exchange
- EXOZ NYSE
- ACHV Nasdaq
- Market Cap
- EXOZ 89.8M
- ACHV 72.5M
- IPO Year
- EXOZ N/A
- ACHV N/A
- Fundamental
- Price
- EXOZ $14.55
- ACHV $2.65
- Analyst Decision
- EXOZ
- ACHV Strong Buy
- Analyst Count
- EXOZ 0
- ACHV 3
- Target Price
- EXOZ N/A
- ACHV $14.33
- AVG Volume (30 Days)
- EXOZ 13.7K
- ACHV 178.4K
- Earning Date
- EXOZ 05-12-2025
- ACHV 05-13-2025
- Dividend Yield
- EXOZ N/A
- ACHV N/A
- EPS Growth
- EXOZ N/A
- ACHV N/A
- EPS
- EXOZ N/A
- ACHV N/A
- Revenue
- EXOZ N/A
- ACHV N/A
- Revenue This Year
- EXOZ N/A
- ACHV N/A
- Revenue Next Year
- EXOZ N/A
- ACHV N/A
- P/E Ratio
- EXOZ N/A
- ACHV N/A
- Revenue Growth
- EXOZ N/A
- ACHV N/A
- 52 Week Low
- EXOZ $8.50
- ACHV $1.84
- 52 Week High
- EXOZ $23.99
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- EXOZ N/A
- ACHV 56.59
- Support Level
- EXOZ N/A
- ACHV $2.32
- Resistance Level
- EXOZ N/A
- ACHV $2.69
- Average True Range (ATR)
- EXOZ 0.00
- ACHV 0.18
- MACD
- EXOZ 0.00
- ACHV 0.03
- Stochastic Oscillator
- EXOZ 0.00
- ACHV 89.19
About EXOZ EXOZYMES INC
EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.